Sanofi (EPA:SAN) has been assigned a €105.00 ($119.32) target price by stock analysts at JPMorgan Chase & Co. in a research note issued on Thursday, Borsen Zeitung reports. JPMorgan Chase & Co.‘s target price would indicate a potential upside of 15.87% from the stock’s previous close.
A number of other research analysts have also recently commented on the company. Jefferies Financial Group set a €120.00 ($136.36) target price on Sanofi in a research note on Wednesday, December 15th. Kepler Capital Markets set a €105.00 ($119.32) target price on Sanofi in a report on Thursday, December 2nd. Barclays set a €90.00 ($102.27) target price on Sanofi in a report on Thursday, December 2nd. Morgan Stanley set a €106.00 ($120.45) price objective on Sanofi in a report on Thursday, October 28th. Finally, Deutsche Bank Aktiengesellschaft set a €80.00 ($90.91) target price on Sanofi in a research report on Friday, December 3rd. One analyst has rated the stock with a sell rating, three have issued a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of €105.00 ($119.32).
Shares of EPA SAN opened at €90.62 ($102.98) on Thursday. The business’s 50 day moving average is €87.98 and its two-hundred day moving average is €86.61. Sanofi has a 1-year low of €63.09 ($71.69) and a 1-year high of €92.97 ($105.65).
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products.
Featured Article: What is a resistance level?
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.